1 - Interna de Formação Específica em Psiquiatria da Infância e da Adolescência, Área de Pediatria, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisboa
2 - Interno de Formação Específica em Psiquiatria da Infância e da Adolescência, Área de Pediatria, Centro Hospitalar Universitário de Lisboa Norte, Lisboa
3 - Psiquiatra da Infância e da Adolescência, Assistente Hospitalar Graduada Sénior, Chefe de Equipa da Clínica do Parque, Área de Pediatria, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisboa
- Reunião internacional sob o formato de poster – 21st WPA World Congress of Psychiatry.
Resumo:
Introdução: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders and frequently continues through adolescence and adulthood. Medication is the single most effective treatment for reducing ADHD symptoms and its use is recommended in children with 6 years and older. Nearly two-thirds of children and adolescents with ADHD also have another mental, emotional, or behavioral disorder, including depression disorders. Bupropion is an antidepressant with a mechanism of action potentially relevant to the treatment of ADHD, used in adults for both depression and smoking cessation and eventually as a third line treatment for ADHD.
Objetivos: The aim of this review was to explore the effectiveness, safety and tolerability of bupropion in children and adolescent with ADHD and depression.
Metodologia: A scientific review was conducted on a careful analysis of the scientific evidence available on the electronic databases: MEDLINE, Embase and the Cochrane Library.
Resultados: There is little empirical evidence to guide the pharmacological treatment for comorbid ADHD and depression as most treatment studies tend to exclude patients with the comorbid disorders. The majority of trials demonstrated bupropion’s efficacy in improving ADHD symptoms in children and adolescents, with effects being superior than placebo and most frequently comparable to methylphenidate. Bupropion also seems effective in improving depressive symptoms in this population, with and without ADHD comorbidity. Side effects did not differ significantly in comparison with stimulants and discontinued medication because of side effects was rare.
Conclusões: Current findings have to be interpreted with caution because of the very limited database and frequent use of small sample sizes. Bupropion seems effective and well-tolerated in children and adolescents with ADHD and ADHD-depression disorders comorbidity. It should be considered for treatment of this population, but more randomized controlled te rials with larger sample sizes are necessary.
Palavras-chave: “adolescent” OU “child” E “bupropion” E “ADHD” E “depression”